Jason’s Journey with ALK+ Metatstatic NSCLC

Opinion
Video

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN.

  • 34-year-old professional rock climber with ALK+ Stage IV metastatic NSCLC, previously healthy with no smoking history.
  • Persistent lower back pain unresponsive to rest and PT, followed by increased fatigue led to initial doctor visit.
  • CT scan revealed a left lung mass with lymph node involvement and a small metastasis on the spine; molecular testing confirmed ALK-positive status.
  • Started on lorlatinib, with manageable GI issues and fatigue as side effects; patient is motivated to return to climbing.
Recent Videos
3 experts in this video
3 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
6 experts are featured in this series.
Related Content
Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.

Radiation Combo Elicits Efficacy in Advanced NSCLC With Brain Metastases

Roman Fabbricatore
February 6th 2025
Article

Radiotherapy plus camrelizumab and platinum-doublet chemotherapy showed manageable toxicity in untreated non–small cell lung cancer with brain metastases.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.

Genomic Features May Define Patient Selection in KRAS-mutated NSCLC

Roman Fabbricatore
February 4th 2025
Article

Adagrasib elicited higher efficacy in combination with mTOR inhibitors vs alone when treating patients with KRASG12C-mutant non–small cell lung cancer.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.

Enhanced Postoperative Recovery May Improve Outcomes in Elderly NSCLC

Roman Fabbricatore
January 28th 2025
Article

Postoperative pulmonary complications were reduced with enhanced recovery after surgery vs control in elderly patients with non–small cell lung cancer.

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.

Local Consolidative Therapy Combo May Extend Survival in Stage IV NSCLC

Roman Fabbricatore
January 22nd 2025
Article

A single-arm phase 2 study assessed local consolidative therapy regimens in patients with oligometastatic stage IV non–small cell lung carcinoma.